Novel Agents Plus Paclitaxel, Carboplatin, Does Not Improve Survival in Endometrial Cancer
Bevacizumab, ixabepilone, and temsirolimus have demonstrated potential activity in endometrial cancer in previous studies.
Adding bevacizumab, temsirolimus, or ixabepilone to paclitaxel and carboplatin (PC) does not improve survival outcomes among patients with advanced/recurrent endometrial cancer compared with PC alone, according to a study published in Gynecologic Oncology.
PC is one of the standards of care for endometrial cancer. Bevacizumab, ixabepilone, and temsirolimus have demonstrated potential activity in previous studies; researchers sought to determine the efficacy and tolerability of adding any of these novel agents to standard therapy.
In this phase 2 study, researchers randomly assigned 349 chemotherapy-naïve patients with advanced or recurrent endometrial cancer to receive PC plus bevacizumab (Arm 1), PC plus temsirolimus (Arm 2), or ixabepilone and carboplatin plus bevacizumab (Arm 3). Patients underwent a computed tomography (CT) scan within the first 4 weeks of treatment and was repeated every 9 weeks for 2 years, then every 3 months until disease progression.
Results showed that progression-free survival (PFS) did not improve significantly in any study arm compared with historical controls (P >.039). Response rates were similar in all study arms; 60% in Arm 1, 55% in Arm 2, and 53% in Arm 3.
Compared with controls, the overall survival duration was significantly prolonged in Arm 1, but not in Arms 2 and 3.
The toxicity profile was similar to those previously reported.
Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer [published online May 24, 2018]. Gynecol Oncol. doi: 10.1016/j.ygyno.2018.05.018